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Hepatic artery thrombosis (HAT) following orthotopic liver
transplantation (OLT) can be a devastating complication that
places the patient at risk of sepsis, biliary problems and graft
loss. In the early years of liver transplantation, retransplantation
was considered the best treatment.1 The need for retransplan-
tation puts additional stress on a limited resource.
In this article, Professor S.T. Fan and his group report an
11-year experience with HAT in 248 liver transplants, 140 of
them from live donors (LDLTs). There were seven episodes of
HAT in six patients. Two of the episodes occurred early (2 and
9 days postoperatively) and required reoperation for thrombec-
tomy or retransplantation; the remaining four occurred later
(21–105 days) and were treated with management of septic
and biliary complications. This treatment was successful in
three of the patients, while the fourth required retransplan-
tation. The authors did not comment on the technical details
of the original transplant procedure. In our experience, HAT
complications occur in patients with problematic arterial
reconstruction due to inadequate recipient inflow. A retro-
spective review of 680 adult liver cadaveric OLTs identified
symptomatic HAT in 11 patients (1.6%).2 Of these, nine (82%)
had inadequate recipient inflow requiring interposition of an
allogeneic iliac graft in seven or anastomosis of an aberrant
right hepatic artery in two.
Professor Fan’s experience with LDLT is noteworthy. LDLTs
are technically demanding, as the arterial reconstruction more
often involves small-calibre vessels, and the extensive procure-
ment operation can lead to inadvertent intimal dissection of
the hepatic arteries. The authors used a microvascular tech-
nique in LDLTs without anticoagulation. The low incidence
of delayed HAT in these patients is a remarkable accomplish-
ment that reflects both impressive technical ability and high-
quality perioperative care.
Of note, delayed HAT was seen in two of eight (25%) LDLT
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patients who had undergone preoperative chemoembolization,
compared with only one of 105 (1%) who had not. This differ-
ence was not seen in the cadaveric group. LDLT is notably
different from cadaveric whole-organ transplantation in the
relative amount of blood flow per gram of liver tissue. Pre-
operative chemoembolization probably causes either sub-
clinical damage to the endothelium or increased vascular
resistance in the graft that may then result in a higher risk of
thrombosis, particularly in the face of increased relative blood
flow. In this report, patients who developed collateralization
fared better than those who did not. Interestingly, LDLT
patients who develop delayed HAT all seem to also have
developed arterial collateralization, which would perhaps sug-
gest that LDLT grafting may stimulate neovascularization as
part of the regenerative process.
The formation of collateral blood supply, which allows
graft salvage with conservative treatment, is a process that
continues to be both a mystery and an area of active research.
One might speculate that delayed HAT develops in a gradual
fashion, leading to increased expression of vascular endothe-
lial growth factors. Were this the case, and with extensive
current investigation and understanding of ischaemia-induced
neovascularization, we may someday see the use of bio-
engineered endothelial growth factors or adjuvants in the pre-
vention and treatment of HAT.3
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